L1-CAM-targeted antibody therapy and 177Lu-radioimmunotherapy of disseminated ovarian cancer

International Journal of Cancer

Volumn 130, Issue 11, 2012, Pages 2715-2721

  Fischer, Eliane ^a   Grünberg, Jürgen ^a   Cohrs, Susan ^a   Hohn, Alexander ^a   Waldner Knogler, Karin ^a   Jeger, Simone ^a   Zimmermann, Kurt ^a   Novak Hofer, Ilse ^a   Schibli, Roger ^a  

^a ETH Zurich   (Switzerland)

Author keywords

L1 CAM; ovarian cancer; radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; LUTETIUM MONOCLONAL ANTIBODY CHCE7 LU 177 CONJUGATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CHCE7; NERVE CELL ADHESION MOLECULE L1; TETRAXETAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; SURVIVAL TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LUTETIUM; MICE; MICE, INBRED BALB C; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859158579     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26321     Document Type: Article

References (35)

1. Hoskins WJ,. Principles and practice of gynecologic oncology, 2nd ed. Philadelphia: Lippincott-Raven, 1997.
2. Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS,. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 2010; 3: 8.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R,. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-200.
4. Bukowski RM, Ozols RF, Markman M,. The management of recurrent ovarian cancer. Semin Oncol 2007; 34: S1-15.
5. Frederick PJ, Straughn JM, Jr., Alvarez RD, Buchsbaum DJ,. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009; 113: 384-90.
6. Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF,. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008; 32: 1145-57.
7. Yap TA, Carden CP, Kaye SB,. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9: 167-81.
8. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF,. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27: 418-25.
9. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR,. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-90.
10. Burger RA,. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25: 2902-8.
11. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK,. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009; 113: 21-7.
12. Milenic DE, Brady ED, Brechbiel MW,. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004; 3: 488-99.
13. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, Epenetos AA, Massuger LF,. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007; 120: 2710-4.
14. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006; 24: 571-8.
15. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P,. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003; 362: 869-75.
16. Weidle UH, Eggle D, Klostermann S,. L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res 2009; 29: 4919-31.
17. Primiano T, Baig M, Maliyekkel A, Chang BD, Fellars S, Sadhu J, Axenovich SA, Holzmayer TA, Roninson IB,. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 2003; 4: 41-53.
18. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P, Kruger A,. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006; 66: 936-43.
19. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Kruger A, Altevogt P,. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008; 27: 1281-9.
20. Novak-Hofer I,. The L1 cell adhesion molecule as a target for radioimmunotherapy. Cancer Biother Radiopharm 2007; 22: 175-84.
21. Wolterink S, Moldenhauer G, Fogel M, Kiefel H, Pfeifer M, Luttgau S, Gouveia R, Costa J, Endell J, Moebius U, Altevogt P,. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 2010; 70: 2504-15.
22. Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R, Grünberg J,. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol 2009; 41: 1572-80.
23. Novak-Hofer I, Cohrs S, Grünberg J, Friedli A, Schlatter MC, Pfeifer M, Altevogt P, Schubiger PA,. Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Lett 2008; 261: 193-204.
24. 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol 2006; 33: 883-9.
25. Knogler K, Grünberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, Altevogt P, Fogel M, Schubiger PA, Novak-Hofer I,. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 2007; 13: 603-11.
26. Novak-Hofer I, Zimmermann K, Mäecke HR, Amstutz HP, Carrel F, Schubiger PA,. Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts. J Nucl Med 1997; 38: 536-44.
27. 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res 2005; 11: 5112-20.
28. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC,. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993; 53: 891-8.
29. Grünberg J, Knogler K, Waibel R, Novak-Hofer I,. High-yield production of recombinant antibody fragments in HEK-293 cells using sodium butyrate. Biotechniques 2003; 34: 968-72.
30. Sgouros G,. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 689-94.
31. Larsson E, Strand SE, Ljungberg M, Jonsson BA,. Mouse S-factors based on Monte Carlo simulations in the anatomical realistic Moby phantom for internal dosimetry. Cancer Biother Radiopharm 2007; 22: 438-42.
32. Segars WP, Tsui BM, Frey EC, Johnson GA, Berr SS,. Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol 2004; 6: 149-59.
33. Keenan MA, Stabin MG, Segars WP, Fernald MJ,. RADAR realistic animal model series for dose assessment. J Nucl Med 51: 471-6.
34. 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 2003; 30: 417-27.
35. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002; 29: 431-42.